AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3391874 — intervention group
Group type: COMPARATOR
Intervention: Pelleted erythromycin base (EB)
Number of subjects: 29
Study 3391874 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected EA tablets
Number of subjects: 29
Study 3391874 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-protected tablets
Number of subjects: 29
Study 3391874 — intervention group
Group type: COMPARATOR
Intervention: Unprotected tablet
Number of subjects: 29
Study 3391874 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected tablet
Number of subjects: 29
Study 3391874 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg acid-protected tablets
Number of subjects: 29
Study 3391874 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg acid-protected tablets
Number of subjects: 29
Study 30599425 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexamethasone (14 mg tapered over 3 days)
Number of subjects: 326
Study 30599425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (target 80–110 mg·dL−1)
Number of subjects: 326
Study 30599425 — intervention group
Group type: EXPERIMENTAL
Intervention: Light anesthesia (Bispectral Index target of 55)
Number of subjects: 326
Study 30599425 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucose control (target 180–200 mg·dL−1)
Number of subjects: 326
Study 30599425 — intervention group
Group type: COMPARATOR
Intervention: Deep anesthesia (Bispectral Index target of 35)
Number of subjects: 326
Study 26999625 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic breathing
Number of subjects: 27
Study 26999625 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 27
Study 25936640 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 50
Study 25936640 — intervention group
Group type: COMPARATOR
Intervention: Single dose of MPH
Number of subjects: 50
Study 25936640 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous MPH administration
Number of subjects: 50
Study 25936640 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS measurements
Number of subjects: 50
Study 23714959 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid intermaxillary fixation (arch bar and intermaxillary fixation for 7 to 12 days)
Number of subjects: 61
Study 23714959 — intervention group
Group type: COMPARATOR
Intervention: Guiding elastic therapy (arch bar and elastics without rigid intermaxillary fixation for 7 to 12 days)
Number of subjects: 61
Study 21323786 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl methacrylate (the liquid part of Unifast TRAD) for 180 seconds
Number of subjects: 90
Study 21323786 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebase II adhesive according to the manufacturer's instructions
Number of subjects: 90
Study 21323786 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl formate, methyl acetate, and a mixture of methyl formate‐methyl acetate at various concentrations (75:25, 50:50, 25:75% v/v) for 15 seconds
Number of subjects: 90
Study 21323786 — intervention group
Group type: COMPARATOR
Intervention: Control group II (negative control)
Number of subjects: 90
Study 21323786 — intervention group
Group type: COMPARATOR
Intervention: Control group I (positive control)
Number of subjects: 90
Study 21323786 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (treated with methyl methacrylate)
Number of subjects: 90
Study 21323786 — intervention group
Group type: EXPERIMENTAL
Intervention: Group IV (treated with Rebase II adhesive)
Number of subjects: 90
Study 21323786 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups V to IX (treated with various concentrations of methyl formate and methyl acetate)
Number of subjects: 90
Study 19188646 — intervention group
Group type: COMPARATOR
Intervention: Nurse-provided asthma education
Number of subjects: 309
Study 19188646 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse + CHW-provided asthma education and home support
Number of subjects: 309
Study 17179873 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interpersonal counseling (TIP-C)
Number of subjects: 192
Study 17179873 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed exercise
Number of subjects: 192
Study 17179873 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 192
Study 15812253 — intervention group
Group type: EXPERIMENTAL
Intervention: OMRON HEM 705 CP upper arm-cuff device with arm in dependent position
Number of subjects: 0
Study 15812253 — intervention group
Group type: EXPERIMENTAL
Intervention: OMRON HEM 705 CP upper arm-cuff device with arm in horizontal position
Number of subjects: 0
Study 15812253 — intervention group
Group type: EXPERIMENTAL
Intervention: OMRON R6 oscillometric wrist-cuff device
Number of subjects: 0
Study 12498339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12498339 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 g/kg alcohol
Number of subjects: 12
Study 12498339 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65 g/kg alcohol
Number of subjects: 12
Study 9744135 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist/patient race and sex matching
Number of subjects: 967
Study 9744135 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist/patient gender matching
Number of subjects: 967
Study 9744135 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 967
Study 8576810 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplemented lipid emulsion
Number of subjects: 49
Study 8576810 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT lipid emulsion
Number of subjects: 49
Study 8576810 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT lipid emulsion
Number of subjects: 49
Study 8576810 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 49
Study 2504377 — intervention group
Group type: EXPERIMENTAL
Intervention: Squeezing a tennis ball as hard as possible for 30 seconds each day for six weeks
Number of subjects: 99
Study 2504377 — intervention group
Group type: COMPARATOR
Intervention: No exercise (after six months without exercise)
Number of subjects: 99
Study 2504377 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-injured arm of women with fractured forearm (n = 13)
Number of subjects: 99
Study 999987 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (40-200 mg per day)
Number of subjects: 155
Study 30531488 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich (NR) supplement
Number of subjects: 10
Study 30531488 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-poor (NP) supplement
Number of subjects: 10
Study 28419206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation (HIIT)
Number of subjects: 151
Study 28419206 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 151
Study 26014487 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation and promotion of health behavior (3-session counseling intervention)
Number of subjects: 55
Study 26014487 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 55
Study 23632723 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of quadrivalent HPV vaccine at 0 and 6 months (n = 259)
Number of subjects: 830
Study 23632723 — intervention group
Group type: COMPARATOR
Intervention: 3 doses of quadrivalent HPV vaccine at 0, 2, and 6 months (n = 261 for girls, n = 310 for young women)
Number of subjects: 830
Study 21196672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg ephedrine
Number of subjects: 150
Study 21196672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg ephedrine
Number of subjects: 150
Study 21196672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg ephedrine
Number of subjects: 150
Study 21196672 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 μg/kg phenylephrine
Number of subjects: 150
Study 21196672 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 150
Study 18059067 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET) group programme, 4 sessions in addition to routine hospital care
Number of subjects: 42
Study 18059067 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 42
Study 17156590 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about physical exercise after one cycle of cytotoxic drugs
Number of subjects: 89
Study 17156590 — intervention group
Group type: COMPARATOR
Intervention: Control group (information about physical exercise after two cycles of cytotoxic drugs)
Number of subjects: 89
Study 12771874 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 41
Study 12771874 — intervention group
Group type: COMPARATOR
Intervention: Potassium
Number of subjects: 41
Study 10460951 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-1-proteinase inhibitor (A1PI) supplementation at 60 mg/kg on days 0, 4, 7, and 14
Number of subjects: 0
Study 10460951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8549573 — intervention group
Group type: COMPARATOR
Intervention: Drink A (2 mmol.l‐1 sodium)
Number of subjects: 6
Study 8549573 — intervention group
Group type: COMPARATOR
Intervention: Drink B (26 mmol.l‐1 sodium)
Number of subjects: 6
Study 8549573 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink C (52 mmol.l‐1 sodium)
Number of subjects: 6
Study 8549573 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink D (100 mmol.l‐1 sodium)
Number of subjects: 6
Study 2196513 — intervention group
Group type: EXPERIMENTAL
Intervention: Single breath maneuver followed by a breath hold
Number of subjects: 21
Study 2196513 — intervention group
Group type: COMPARATOR
Intervention: Panting technique followed by a breath hold
Number of subjects: 21
Study 390987 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 70
Study 390987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 31519167 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified cereal group
Number of subjects: 180
Study 31519167 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat group
Number of subjects: 180
Study 31519167 — intervention group
Group type: COMPARATOR
Intervention: Local cereal group
Number of subjects: 180
Study 31519167 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 180
Study 27449714 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (30 mg/kg) infused intravenously 15 minutes before tourniquet inflation
Number of subjects: 180
Study 27449714 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (30 mg/kg) infused intravenously 15 minutes after tourniquet inflation
Number of subjects: 180
Study 27449714 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (30 mg/kg) infused intravenously on tourniquet deflation
Number of subjects: 180
Study 27449714 — intervention group
Group type: COMPARATOR
Intervention: No tranexamic acid administration
Number of subjects: 180
Study 25167348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided interscalene block
Number of subjects: 110
Study 25167348 — intervention group
Group type: COMPARATOR
Intervention: Neurostimulation-guided interscalene block
Number of subjects: 110
Study 22052584 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Number of subjects: 226
Study 22052584 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 226
Study 22052584 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 120 mg
Number of subjects: 226
Study 22052584 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 240 mg
Number of subjects: 226
Study 22052584 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 226
Study 22052584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 22052584 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg vs Allopurinol
Number of subjects: 226
Study 19464413 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mixed pulmonary hypertension (MPH)
Number of subjects: 171
Study 17365917 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (60 mg/day) + Amoxicillin (750 mg/day) + Clarithromycin (400 mg/day) for 7 days
Number of subjects: 31
Study 17365917 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (60 mg/day) + Clarithromycin (400 mg/day) for 7 days
Number of subjects: 31
Study 15129381 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced access appointment system
Number of subjects: 2
Study 15129381 — intervention group
Group type: COMPARATOR
Intervention: Traditional access system
Number of subjects: 2
Study 12029279 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐cornered flap
Number of subjects: 14
Study 12029279 — intervention group
Group type: COMPARATOR
Intervention: Szmyd flap
Number of subjects: 14
Study 12029279 — intervention group
Group type: EXPERIMENTAL
Intervention: Both flaps
Number of subjects: 14
Study 9862244 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 56697 (artemether 20 mg + benflumetol 120 mg) 4 x 4 tablets over 48 h
Number of subjects: 260
Study 9862244 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 56697 (artemether 20 mg + benflumetol 120 mg) 4 x 2 tablets over 48 h
Number of subjects: 260
Study 9862244 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 56697 (artemether 20 mg + benflumetol 120 mg) 3 x 4 tablets over 24 h
Number of subjects: 260
Study 7623073 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) with 20 or 25 Gy delivered in a single fraction
Number of subjects: 36
Study 7623073 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 36
Study 7623073 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 36
Study 2618634 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage treatment
Number of subjects: 40
Study 2618634 — intervention group
Group type: COMPARATOR
Intervention: Two-stage treatment
Number of subjects: 40
Study 2618634 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 35192 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 44
Study 35192 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 30 mg
Number of subjects: 44
Study 35192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipotassium clorazepate 15 mg
Number of subjects: 44
Study 31900758 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum CRP levels (per standard deviation increase)
Number of subjects: 418642
Study 31900758 — intervention group
Group type: EXPERIMENTAL
Intervention: High CRP levels (> 3 mg/L)
Number of subjects: 418642
Study 31900758 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analyses using different MR models
Number of subjects: 418642
Study 31900758 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable MR adjusting for other AMD risk factors
Number of subjects: 418642
Study 31447131 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin-laropiprant (2000/40 mg/d)
Number of subjects: 25673
Study 28615356 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane (provided as concentrated broccoli sprout extract)
Number of subjects: 0
Study 28615356 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Number of subjects: 0
Study 26179616 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement with added micronutrients
Number of subjects: 1815
Study 26179616 — intervention group
Group type: COMPARATOR
Intervention: Lipid-based nutrient supplement without added micronutrients
Number of subjects: 1815
Study 26179616 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in serum CRP from recruitment to week 6
Number of subjects: 1815
Study 26179616 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in serum CRP
Number of subjects: 1815
Study 23354657 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical hemoglobin solution added to standard wound care
Number of subjects: 72
Study 23354657 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care without hemoglobin
Number of subjects: 72
Study 21859640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosolvin (15 mg/kg per day)
Number of subjects: 100
Study 21859640 — intervention group
Group type: COMPARATOR
Intervention: Control (no respiratory drug)
Number of subjects: 100
Study 18982311 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendons (HT) graft
Number of subjects: 36
Study 18982311 — intervention group
Group type: COMPARATOR
Intervention: Patellar tendon (PT) graft
Number of subjects: 36
Study 18982311 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 17885566 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track Program
Number of subjects: 891
Study 17885566 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 891
Study 16437139 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential ATRA and chemotherapy
Number of subjects: 18
Study 16437139 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA treatment
Number of subjects: 18
Study 16437139 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of mutant subclones
Number of subjects: 18
Study 16437139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-therapy detection
Number of subjects: 18
Study 16437139 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent ATRA therapy
Number of subjects: 18
Study 12579384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg i.v. preoperatively followed by 8 mg every 8 h for a total of 24 mg in the first 24 h
Number of subjects: 66
Study 12579384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg i.v. bolus before the end of the operation followed by 8 mg every 8 h for a total of 24 mg in the first 24 h
Number of subjects: 66
Study 12579384 — intervention group
Group type: COMPARATOR
Intervention: Placebo before and after the operation and for the first 24 h
Number of subjects: 66
Study 10770346 — intervention group
Group type: COMPARATOR
Intervention: ZDV/ddI
Number of subjects: 170
Study 10770346 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV/ddI/NVP
Number of subjects: 170
Study 9020808 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic criterion for response anticipation in the absence of a warning stimulus
Number of subjects: 0
Study 9020808 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimuli discrimination task
Number of subjects: 0
Study 1746711 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-stat management (group I)
Number of subjects: 42
Study 1746711 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-stat management (group II)
Number of subjects: 42
Study 1746711 — intervention group
Group type: COMPARATOR
Intervention: Control values (normothermia)
Number of subjects: 42
Study 7174622 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 46
Study 7174622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 30941063 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitlink intervention with peer worker support and referral to the Victorian Quitline for an 8-week cognitive behavioral intervention and nicotine replacement therapy (NRT)
Number of subjects: 382
Study 30941063 — intervention group
Group type: COMPARATOR
Intervention: No further intervention (control group)
Number of subjects: 382
Study 28785986 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/Paclitaxel (CP)
Number of subjects: 124
Study 28785986 — intervention group
Group type: COMPARATOR
Intervention: Platinum/5-Fluorouracil (PF)
Number of subjects: 124
Study 28785986 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 124
Study 26112745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 28
Study 26112745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23392737 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin treatment
Number of subjects: 0
Study 23392737 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21206285 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage right unilateral (RUL) ECT
Number of subjects: 184
Study 21206285 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dosage bilateral (BL) ECT
Number of subjects: 184
Study 21206285 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (VEN) plus lithium (Li)
Number of subjects: 184
Study 21206285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) plus lithium (Li)
Number of subjects: 184
Study 21206285 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation treatment with VEN + Li
Number of subjects: 184
Study 21206285 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation treatment with NT + Li
Number of subjects: 184
Study 21206285 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission status
Number of subjects: 184
Study 21206285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance
Number of subjects: 184
Study 19273782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate therapy (n = 1509)
Number of subjects: 3026
Study 19273782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate therapy with upper-tertile HDL-C response (>8 mg/dL)
Number of subjects: 3026
Study 19273782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate therapy with lower-tertile HDL-C response (<=8 mg/dL)
Number of subjects: 3026
Study 19273782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative probability of death at 16 years for bezafibrate with upper-tertile HDL-C response
Number of subjects: 3026
Study 19273782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative probability of death at 16 years for bezafibrate with lower-tertile HDL-C response
Number of subjects: 3026
Study 19273782 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (n = 1517)
Number of subjects: 3026
Study 17970879 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate 300 mg q.i.d., lansoprazole 30 mg b.i.d., tetracycline 500 mg q.i.d., metronidazole 500 mg t.i.d. (BLTM group) for 14 days
Number of subjects: 240